Funding for this research was provided by:
ZonMw (PTO grant 95105015)
Hersenstichting (PTO grant 95105015)
Alexion Pharmaceuticals (ISR grant 100237)
Article History
Received: 10 June 2020
Accepted: 22 October 2020
First Online: 25 November 2020
Ethics approval and consent to participate
: The ethics committee of the UMC Utrecht approved this study (reference number: 17-933). Written informed consent will be obtained from the patient or legally authorized representative by the investigators or physician on call. Patients who are enrolled in the study are covered by the clinical trial insurance of the UMC Utrecht. The study will be conducted in accordance with the Good Clinical Practice E6(R2) guidelines and the current version of the Declaration of Helsinki.
: Not applicable
: Eculizumab and research funding are provided by Alexion Pharmaceuticals under the Global Investigator-Sponsored Research Program.